脂质体多柔比星联合异环磷酰胺治疗骨肉瘤的临床疗效及对患者血清炎性因子水平、肢体活动功能及生活质量的影响  

Clinical efficacy of liposome doxorubicin combined with ifosfamide in the treatment of patients with osteosarcoma and its influence on serum inflammatory factors,limb function and quality of life

作　　者：杨玥[1] 陈澜[1] YANG Yue;CHEN Lan(Department of Orthopedics,Chengdu Third People’s Hospital,Chengdu 610000,Sichuan,China)

机构地区：[1]成都市第三人民医院骨科,成都610000

出　　处：《癌症进展》2020年第16期1704-1707,共4页Oncology Progress

摘　　要：目的探讨脂质体多柔比星联合异环磷酰胺治疗骨肉瘤的临床疗效及对患者血清炎性因子水平、肢体活动功能及生活质量的影响。方法采用随机数字表法将98例骨肉瘤患者分为常规组和观察组,每组49例。常规组患者采用多柔比星联合异环磷酰胺方案化疗,观察组患者采用脂质体多柔比星联合异环磷酰胺方案化疗。比较两组患者的临床疗效、治疗前后的血清炎性因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-10(IL-10)]水平及不良反应发生率。随访1年后,分别采用美国骨肿瘤学会评分系统(MSTS 93)和健康调查简表(SF-36)评价两组患者的肢体活动功能和生活质量。结果观察组患者的临床疗效明显优于常规组,差异有统计学意义(P﹤0.01);观察组患者的疾病控制率为95.92%,高于常规组的81.63%,差异有统计学意义(P﹤0.05)。化疗前,两组患者的血清CRP、TNF-α、IL-10水平比较,差异均无统计学意义(P﹥0.05);化疗后,两组患者的血清CRP、TNF-α水平均低于本组化疗前,血清IL-10水平高于本组化疗前,且观察组患者的血清CRP、TNF-α水平均低于常规组,血清IL-10水平高于常规组,差异均有统计学意义(P﹤0.05)。观察组患者的不良反应总发生率为46.94%,明显低于常规组的75.51%(P﹤0.01)。随访1年,观察组患者的MSTS 93、SF-36评分均明显高于常规组(P﹤0.01)。结论脂质体多柔比星联合异环磷酰胺能够提高骨肉瘤患者的临床疗效,促进患者机体内炎性因子表达平衡机制的恢复,改善患者的肢体活动功能与生活质量。Objective To investigate the clinical efficacy of liposome doxorubicin combined with ifosfamide in the treatment of patients with osteosarcoma and its influence on serum inflammatory factors,limb function and quality of life.Method According to random number table method,98 patients with osteosarcoma were divided into conventional group and observation group,49 cases in each group.The conventional group was treated with doxorubicin combined with ifosfamide chemotherapy,and the observation group was treated with liposome doxorubicin combined with ifosfamide chemotherapy.The clinical efficacy of the two groups was evaluated,the expression levels of serum inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-10(IL-10)]in the two groups before and after treatment were observed,and the occurrence of adverse reactions during chemotherapy in the two groups was counted.After one year of follow-up,Musculoskeletal Tumor Society 93(MSTS 93)and the MOS 36-item short form health survey(SF-36)were used to evaluate the limb function and quality of life in the two groups.Result The clinical efficacy in the observation group was better than that in the conventional group(P<0.05).The disease control rate of patients in the observation group was 95.92%,which was higher than that of 81.63%in the conventional group(P<0.05).Before chemotherapy,there was no statistically significant difference in the expression levels of serum CRP,TNF-αand IL-10 between the two groups(P>0.05).After chemotherapy,the serum levels of CRP,TNF-αwere decreased and IL-10 was increased in the two groups compared with those before chemotherapy(P<0.05);in addition,the serum levels of CRP and TNF-αin the observation group were lower than those in the conventional group,and the serum level of IL-10 was higher than that in the conventional group,showing statistical significance(P<0.05).The incidence of total adverse reactions was 46.94%in the observation group,which was lower than that of 75.51%in the conventional group(P<0.01

关 键 词：骨肉瘤 化疗 肢体活动功能 炎性因子 脂质体多柔比星 异环磷酰胺 

分 类 号：R738.1[医药卫生—肿瘤]